THE NEUTRALIZING ANTIBODY TEST

USING THE EVE PATIENT APP

  • IOS and Android
  • HIPAA compliant
  • Real-time test processing tracker
  • Barcode/QR code scanner
  • Health Cards
  • Securely upload and store vaccine cards
  • Notification to retest
  • Alerts

FOUR SIMPLE STEPS TO REGISTER THE TEST ON THE APP

DOWNLOAD THE APP

SCAN THE LABEL BARCODE

ANSWER THE SURVEY QUESTIONS

REGISTER THE SPECIMEN

STEP 1

DOWNLOAD THE APP

STEP 2

SCAN THE LABEL BARCODE

STEP 3

ANSWER THE SURVEY QUESTIONS

STEP 4

REGISTER THE SPECIMEN

THE NEUTRALIZING ANTIBODY TEST

UNDERSTANDING THE IMMUNOCARD™

The ImmunoCard™ is accessed by tapping on the “Health Card” icon on the bottom menu of the EVE App.

ImmunoCard™ is designed to update to new types of immunity tests as they become available.

The ImmunoCard™ provides the user with an easy-to-understand user interface which summarizes all the important points of the neutralizing antibody tests:

  • Positive neutralizing activity (currently protected against getting serious infection from SARS-CoV-2)
  • Negative Neutralizing activity (currently not protected against getting serious infection from SARS-CoV-2)
  • Percentage of neutralizing antibody
  • Date for retest*
  • Access to full laboratory report

THE COMPREHENSIVE IMMUNITY ASSAY

UNDERSTANDING THE IMMUNOCARD™

A green tab means you have adequate neutralizing antibodies present (>30%)

A red tab means you do not have adequate neutralizing antibodies present (<30%)

Percentage of protection for SARS-CoV-2 ( Learn More )
1

This defines the percentage of neutralizing antibodies that you have specific to the SARS-CoV-2 virus. A positive result is defined as > 30%

2

This section defines when you should get a retest as defined by the parameters established in the FDA EUA approval. The app will notify you when a retest is  suggested.

Percentage of protection for the Omicron Variant ( Learn More )

3

This defines the percentage of neutralizing antibodies that you have specific to the Omicron Variant. A positive result is defined as > 30%

Recent exposure to COVID-19 ( Learn More )

4

A positive N1 test  indicates the presence of detectable antibodies to N1 and suggests a past infection with the SARS-CoV-2 virus in this individual.

A negative N1 test suggests that a recent infection with the SARS-CoV-2 virus in this individual has not occurred.

Percentage of protection for SARS-CoV-2 ( Learn More )

1

This defines the percentage of neutralizing antibodies that you have specific to the SARS-CoV-2 virus. A positive result is defined as > 30%

2

This section defines when you should get a retest as defined by the parameters established in the FDA EUA approval. The app will notify you when a retest is  suggested.

Percentage of protection for the Omicron Variant ( Learn More )

3

This defines the percentage of neutralizing antibodies that you have specific to the Omicron Variant. A positive result is defined as > 30%

Recent exposure to COVID-19      ( Learn More )

4

A positive N1 test  indicates the presence of detectable antibodies to N1 and suggests a past infection with the SARS-CoV-2 virus in this individual.

A negative N1 test suggests that a recent infection with the SARS-CoV-2 virus in this individual has not occurred.

The neutralizing antibody test has been authorized by the FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of the declaration that circumstances exist for justifying the authorization of emergency use in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564 (b) (1) of the Act, 21 U.S.C. 360bbb-3 (b) (1), unless the authorization is terminated or revoked sooner. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens.

The semi-quantitative and Omicron neutralizing antibody components of the test have been modified under CLIA guidelines to report total blocking activity percentages (%), quantification of blocking antibodies in IU/ml, anti-Omicron variant neutralizing antibody blocking activity percentages (%), automation, and finger stick specimens.

This N1 fragment antibody test was developed, and its performance characteristics determined, by Healix Pathology, LLP laboratory (CLIA# 06D2174124). It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA and is qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

This N1 fragment antibody test was developed, and its performance characteristics determined, by Healix Pathology, LLP laboratory (CLIA# 06D2174124). It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA and is qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

The semi-quantitative and Omicron neutralizing antibody components of the test have been modified under CLIA guidelines to report total blocking activity percentages (%), quantification of blocking antibodies in IU/ml, anti-Omicron variant neutralizing antibody blocking activity percentages (%), automation, and finger stick specimens.

This N1 fragment antibody test was developed, and its performance characteristics determined, by Healix Pathology, LLP laboratory (CLIA# 06D2174124). It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA and is qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.